Drug Type Small molecule drug |
Synonyms Zidebactam/cefepime intravenous |
Target |
Mechanism PBP3 inhibitors(Penicillin-binding protein 3 inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H24N6O5S2 |
InChIKeyHVFLCNVBZFFHBT-ZKDACBOMSA-N |
CAS Registry88040-23-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute pyelonephritis | Phase 3 | US | 28 Aug 2022 | |
Acute pyelonephritis | Phase 3 | CN | 28 Aug 2022 | |
Acute pyelonephritis | Phase 3 | BG | 28 Aug 2022 | |
Acute pyelonephritis | Phase 3 | EE | 28 Aug 2022 | |
Acute pyelonephritis | Phase 3 | IN | 28 Aug 2022 | |
Acute pyelonephritis | Phase 3 | LT | 28 Aug 2022 | |
Acute pyelonephritis | Phase 3 | MX | 28 Aug 2022 | |
Acute pyelonephritis | Phase 3 | PE | 28 Aug 2022 | |
Acute pyelonephritis | Phase 3 | PL | 28 Aug 2022 | |
Complicated urinary tract infection | Phase 3 | US | 28 Aug 2022 |